38 completed, 6 recruiting, 4 terminated, 2 not yet recruiting. 21 Phase 2, 20 Phase 1, 16 Phase 3.
By phase and status
Follow Insmed Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
Treprostinil Palmitil Inhalation Powder, Placebo - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Not yet recruiting | Insmed Incorporated | 800 | 2026-12-01 | 2026-09-04 |
A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
Brensocatib, Midazolam - Healthy Volunteers | Phase 1 | Not yet recruiting | Insmed Incorporated | 26 | 2026-10-29 | 2026-10-05 |
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants
INS1033, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Insmed Incorporated | 116 | 2026-08-25 | 2026-09-25 |
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Treprostinil Palmitil Inhalation Powder, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Recruiting | Insmed Incorporated | 344 | 2026-07-21 | 2026-10-13 |
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Treprostinil Palmitil Inhalation Powder, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Recruiting | Insmed Incorporated | 344 | 2026-07-20 | 2026-08-13 |
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Treprostinil Palmitil Inhalation Powder - Hepatic Impairment | Phase 1 | Recruiting | Insmed Incorporated | 30 | 2026-07-14 | 2026-09-11 |
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Treprostinil Palmitil Inhalation Powder, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Recruiting | Insmed Incorporated | 344 | 2026-01-07 | 2026-10-13 |
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
TPIP F2, TPIP F3 - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 42 | 2025-08-19 | 2025-11-21 |
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Brensocatib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Insmed Incorporated | 214 | 2024-12-16 | 2026-06-29 |
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Brensocatib Oral Solution, Brensocatib Oral Tablet - Healthy Participants | Phase 1 | Completed | Insmed Incorporated | 24 | 2024-04-30 | 2024-06-13 |
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
Brensocatib - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 20 | 2023-12-27 | 2024-01-22 |
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
OpSCF, Placebo - Atopic Dermatitis | Phase 2 | Completed | Insmed Incorporated | 50 | 2023-11-21 | 2026-09-11 |
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis Without Nasal Polyps | Phase 2 | Completed | Insmed Incorporated | 288 | 2023-10-30 | 2026-09-30 |
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Brensocatib, Clarithromycin - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 22 | 2023-07-28 | 2023-12-11 |
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Treprostinil Palmitil Inhalation Powder, Placebo - Pulmonary Hypertension, Interstitial Lung Disease | Phase 2 / Phase 3 | Completed | Insmed Incorporated | 31 | 2023-05-11 | 2026-04-23 |
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
Brensocatib, Rifampin, Esomeprazole - Healthy Volunteers | Phase 1 | Completed | Insmed Incorporated | 32 | 2023-05-10 | 2023-08-21 |
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Treprostinil Palmitil, Placebo - Pulmonary Arterial Hypertension | Phase 2 / Phase 3 | Active not recruiting | Insmed Incorporated | 91 | 2023-03-07 | 2026-10-20 |
Development of a Canadian Bronchiectasis and NTM Database
Bronchiectasis, Non-Tuberculous Mycobacterial Pneumonia | | Recruiting | University of Calgary | 2000 | 2023-01-01 | 2023-11-22 |
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Treprostinil Palmitil, Placebo - Pulmonary Hypertension | Phase 2 | Completed | Insmed Incorporated | 39 | 2022-12-22 | 2025-03-17 |
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Brensocatib - Hepatic Impairment | Phase 1 | Completed | Insmed Incorporated | 30 | 2022-10-04 | 2023-07-19 |
Showing 20 of 54. Sign in to see all of them.
Conditions studied
Cystic Fibrosis (8) · Respiratory Tract Infections (7) · Lung Diseases, Interstitial (6) · Hypertension, Pulmonary (5) · Mycobacterium Infections, Nontuberculous (5) · Pulmonary Arterial Hypertension (5) · Bronchiectasis (3) · Mycobacterium avium-intracellulare Infection (2) · Pseudomonas Infections (2) · COVID-19 (1) · Dermatitis, Atopic (1) · Eczema (1) · Hidradenitis Suppurativa (1) · Laron Syndrome (1) · Lung Diseases (1)
Interventions
brensocatib (16) · Inhalation (8) · Azithromycin (2) · Ethambutol (2) · Insulin-Like Growth Factor I (2) · Clarithromycin (1) · Esomeprazole (1) · Masoprocol (1) · Midazolam (1) · Moxifloxacin (1) · Nebulizers and Vaporizers (1) · Rifampin (1) · SPI-77, liposomal (1) · hexadecyl-treprostinil (1) · treprostinil (1)
Countries
United States (37) · Germany (14) · Spain (14) · Belgium (13) · Italy (13) · United Kingdom (13) · Australia (12) · Argentina (11) · Poland (11) · Denmark (10) · Canada (9) · Serbia (9) · Austria (8) · Hungary (8) · Bulgaria (7)
Top investigators
Gina Eagle, MD (8) · Carlos Fernandez, MD (1) · Gina Eagle (1) · James Chalmers (1) · Kenneth Attie, MD (1) · Kevin L Winthrop, MD, MPH (1) · Kevin Mange, MD (1) · Renu Gupta, MD (1) · Richard Gorlick, MD (1) · Richard Moxley, M.D. (1)
Results publications
PMID 33595792, PMID 41186908, PMID 21971890, PMID 23255417, PMID 23749840, PMID 27748623, PMID 30216086, PMID 31451351, PMID 32897034, PMID 33326356, PMID 33887244, PMID 34144923, PMID 35411669, PMID 35976570, PMID 36070132, PMID 37198686, PMID 37419144, PMID 37538173, PMID 38277865, PMID 39040578, PMID 39574348, PMID 39938076, PMID 40198465, PMID 40267423, PMID 40753522, PMID 41100013, PMID 41519018, PMID 41586857, PMID 41915555, PMID 42461571, PMID 42814876
NIH funding
2023 (4), 2025 (2), 2014 (1), 2015 (1), 2017 (1)